Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR1 | P30872 | 1/20 | 0.42 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.42 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.42 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.42 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | TACR2 | P21452 | 3/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 9/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.41 |
| ▸ | CDC25B | P30305 | 7/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 3/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2199939 | 1.00 | SSTR1 (0.42) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL5271970 | 0.94 | TACR2 (0.44) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL5270929 | 0.83 | SLC5A2 (0.44) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL20139456 | 0.81 | HTR1A (0.38) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL12605357 | 0.80 | SSTR1 (0.42) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL5203758 | 0.80 | SSTR1 (0.47) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL20140067 | 0.80 | SSTR1 (0.41) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL13257998 | 0.79 | SSTR4 (0.42) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL12425666 | 0.79 | PTPN1 (0.41) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL13257971 | 0.79 | SSTR4 (0.44) | SSTR1SSTR2SSTR4SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977466-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20090069252-A1 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069252-A1 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF | SLC5A1, SLC5A2, SLC2A1 | SSTR1 650/4885SSTR2 781/4885SSTR4 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.